HIV IN MOTHERS AND INFANTS--IMMUNITY AND EARLY DIAGNOSIS

我们建议评估与母婴艾滋病毒相关的母体因素。 在海地和美国妇女中传播。我们将确定数量和 潜伏和主动复制艾滋病毒的形式与确定的关系 与母体对艾滋病毒的免疫反应和 母婴传播。定量聚合酶链式反应- 将开发酶免疫分析(PCR-EIA)来定量基因组mRNA， 并用单剪接和双剪接法确定HIV基因的形式 孕妇外周血和脐带血中的物质。我们有 测定了21名海地感染者的基因序列， 确定了我们人口的共识序列。来自中国的多肽 将制作原理中和域(PND)来确定 针对PND以外表位的抗体的贡献 到全面的中和活动。此外，我们还将测量ADCC 母体血清容量、病毒特异性细胞毒性T淋巴细胞(CTL)、 以及CD4和CD8阳性细胞的水平来确定是否 免疫反应与母体病毒载量或 母婴传播。 为了识别8周以下感染艾滋病毒的婴儿，我们将评估 DNA和RNA、抗HIV-IgA和p24抗原血症的新型聚合酶链式反应检测方法 酸水解后，HIV诱导T细胞增殖，并特异性 CTL反应在出生时、1~2个月龄和3~6个月龄时。 婴儿的这些反应的时间将被用来估计 婴儿在出生前和出生时感染的比例。 这些调查将利用可从以下地点获得的储存标本 超过250名未感染婴儿的艾滋病毒血清阳性母亲，50名 感染婴儿，以及两项正在进行的队列研究，招募了150多人 血清阳性妇女一年所生的婴儿。

We propose to assess maternal factors associated with maternal-infant HIV transmission in Haitian and U.S. women. We will determine the quantity and form of latent and actively replicating HIV and determine the relationship with the maternal immune response to HIV and the probability of maternal-infant transmission. Quantitative Polymerase chain reaction - Enzyme immunoassay (PCR-EIA) will be developed to quantify genomic mRNA, and singly and double spliced mRNA to determine the form of HIV genetic material in maternal peripheral blood and umbilical cord blood. We have determined the genetic sequence from 21 infected Haitian adults and determined the consensus sequence for our population. Peptides from the principle neutralizing domain (PND) will be made to determine the contribution of antibodies against epitopes other than those from the PND to overall neutralizing activity. Furthermore, we will measure the ADCC capacity of maternal sera, viral specific cytotoxic T-lymphocytes (CTL), and the level of CD4 and CD8 positive cells to determine if the level of immune responsiveness is associated with maternal viral load or maternal-infant transmission. To identify HIV infected infants under 8 weeks of age we will evaluate novel PCR assays for DNA and RNA, anti-HIV IgA, and p24 antigenemia following acid hydrolysis HIV induced T-cell proliferation, and specific CTL responses at birth, 1 to 2 months of age and at 3 to 6 months of age. The timing of these responses in infants will be used to estimate what proportion of infants were infected before and at the time of birth. These investigations will take advantage of stored specimens available from more than 250 HIV seropositive mothers of uninfected infants, 50 mothers of infected infants, and two ongoing cohort studies that enroll more than 150 infants born to seropositive women a year.